RxDoctor Payments DataLook up a doctor →

Stephen Devenport, MD

Family Medicine · Riverton, UTNPI 1093730467

Payments from drug & device makers

$1,281,148in general payments, 2019–2025

Across 280 payments — averaging $4575.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$442K
  • Covis Pharma GmbH$225K
  • Astrazeneca UK Limited$181K
  • Astellas Pharma Global Development$160K
  • AstraZeneca$158K
  • BD$68K
  • plus $47K from 40 others
$1,989in research payments, 2019–2025

Across 3 payments — averaging $663.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Chiesi USA, Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.42$442,005
Covis Pharma GmbH2$224,975
Astrazeneca UK Limited1$180,520
Astellas Pharma Global Development67$160,486
AstraZeneca17$157,954
BD3$67,948
Pfizer7$24,507
Chiesi USA, Inc.7$20,409
Astellas Pharma US Inc17$325
Boehringer Ingelheim13$252
Abbott9$195
Novo Nordisk12$172
Ironshore Pharmaceuticals Inc.8$163
AbbVie(2 entities)6$129
GSK7$120
Johnson & Johnson6$93
Lilly USA, LLC6$86
Supernus Pharmaceuticals, Inc.4$73
Phathom Pharmaceuticals, Inc.4$60
Sanofi-aventis U.S. LLC4$53
Merck3$52
Sobi, Inc3$47
Exact Sciences3$42
Lundbeck LLC3$42
Amgen2$39
Gilead2$32
Bayer2$31
Axsome Therapeutics, Inc.1$26
Amarin Pharma, Inc.2$25
Daiichi Sankyo Inc.1$22
Inspire Medical Systems, Inc.1$21
Almatica Pharma LLC1$20
Mylan Specialty L.p.1$19
Cranial Technologies, Inc1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Grifols USA, LLC1$18
Dexcom, Inc.1$18
Therapeuticsmd, Inc.1$17
Dynavax Technologies Corporation1$16
Sunovion Pharmaceuticals Inc.1$16
Organon1$16
Shire North American Group Inc1$15
Azurity Pharmaceuticals, Inc.1$15
Kowa Pharmaceuticals America, Inc.1$15
Tris Pharma Inc1$14
Takeda Pharmaceuticals U.S.A., Inc.1$12

How this compares

$1,281,148 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah →

Medicare billing

Part B allowed, 2024
$36,466
Medicare patients
93
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Riverton

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →